drugset
drugset / Trial / NCT04000555

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

NCT04000555 ↗

Phase 4 Terminated 26 enrolled University of South Florida
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.

Timeline

Start
2019-09-01
Primary completion
2022-06-11
Completion
2022-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 125 mg Oral

Indications

Clostridium difficile colitis